Innate Pharma (traded under the ticker symbol IPHA on Nasdaq and Euronext Paris) trades at an absolute share price that places it within the general valuation range often associated with micro-cap or lower-priced equities. However, classifying it strictly as a conventional speculative penny stock overlooks its status as a publicly listed, clinical-stage oncology biopharmaceutical enterprise backed by institutional investors, global pharmaceutical licensing deals, and structured regulatory oversight.